+

WO2006113925A2 - Composition et utilisation de phyto-percolate pour le traitement d'une maladie - Google Patents

Composition et utilisation de phyto-percolate pour le traitement d'une maladie Download PDF

Info

Publication number
WO2006113925A2
WO2006113925A2 PCT/US2006/015302 US2006015302W WO2006113925A2 WO 2006113925 A2 WO2006113925 A2 WO 2006113925A2 US 2006015302 W US2006015302 W US 2006015302W WO 2006113925 A2 WO2006113925 A2 WO 2006113925A2
Authority
WO
WIPO (PCT)
Prior art keywords
phyto
percolate
derivative
compound
animal
Prior art date
Application number
PCT/US2006/015302
Other languages
English (en)
Other versions
WO2006113925A3 (fr
Inventor
Tiffany Thomas
Original Assignee
Health Enhancement Products, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2005/013375 external-priority patent/WO2005112987A2/fr
Application filed by Health Enhancement Products, Inc. filed Critical Health Enhancement Products, Inc.
Priority to CA002625818A priority Critical patent/CA2625818A1/fr
Priority to EP06758513A priority patent/EP1928247A4/fr
Priority to US12/067,735 priority patent/US8586053B2/en
Publication of WO2006113925A2 publication Critical patent/WO2006113925A2/fr
Priority to US11/606,676 priority patent/US7807622B2/en
Publication of WO2006113925A3 publication Critical patent/WO2006113925A3/fr
Priority to US12/897,574 priority patent/US8791060B2/en
Priority to US14/558,516 priority patent/US10166270B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae

Definitions

  • This invention relates generally to methods and compositions for treating and preventing human diseases, disorders, and conditions using a preparation of a phyto- percolate isolated from a complex mixture of fresh water algae and other microorganisms.
  • Enzymes have a very important use within biochemical cycles in the human body.
  • proteolytic enzymes are responsible for the body's detoxification processes. As humans age and chronic disease processes progress, a deficiency of the proteolytic enzymes that carry out the body's waste detoxification processes may be experienced. This enzymatic deficiency aids in the production of a chronic hyper-inflammatory state, and the disease process becomes much more complex.
  • Enzymes are the catalysts that control and direct all metabolic processes. Without adequate enzymes in the body, chaos reigns and the immune system and other metabolic processes become less efficient, making tissue repair slow and poorly replicated.
  • Proteolytic enzymes, or proteases are enzymes capable of breaking down proteins by cleaving peptide bonds. They are produced and utilized by every living organism on Earth for protection, nutrient breakdown and assimilation, and waste removal. Many degenerative diseases stem from proteolytic enzyme deficiencies, leading to the inadequate removal of carcinogenic wastes from the body.
  • the immune system which helps protect us from diseases including cancer, cardiovascular disease, and other immune deficient or deregulated disorders, can become ineffective because of advanced disease state or age.
  • Immune deficiency caused by disease state or advancing age can impair benefits received from the use of therapeutic drugs that may be taken for the treatment of these various disorders.
  • Therapeutic drugs may lose their effectiveness in a compromised immune system as a disease state progresses due to metabolic dysfunction or poor therapeutic drug assimilation. witn advancing age, " h ⁇ a ⁇ s experience an increasing accumulation of damage resulting from environmental influences that are believed to be toxic.
  • An observed effect associated with aging is a less accurate tissue repair process, including DNA mutation repair. Because of these alterations, pathogens (e.g., microbes), and environmental toxins (e.g., radiation and chemical compounds) increasingly produce deleterious effects.
  • Tri ' is"gfadually'fficfeasin " g cellular starvation affects the functions of the brain, heart, kidneys, muscles, joints and other vital systems.
  • Tissue destruction also activates the body's coagulation, or blood- clotting, mechanism, generating a barrage of Inlra-"asc ⁇ !ar fhrn tibi, ⁇ r blood dots, and blood-thickening fibrin, that can precipitate strokes, heart attacks, pulmonary emboli, kidney damage, and phlebitis.
  • the resulting pathological agents secondary to this influence of white cell activity create an ongoing destructive pattern upon local surrounding tissue, the endothelial cells that line the vascular bed, and the epithelial cells lining the intestinal tract. Not only is there destructive activity upon the above-mentioned tissues but also there is oxidative breakdown or pathological activation of the coagulation factors.
  • This soluble fibrin not only negatively influences general capillary circulation but also kidney filtration, oxygen exchange within the alveoli of the lungs, and oxygenation of brain tissue. It not only thickens the blood, but is in itself an oxidative free radical, and contributes to the degenerative oxidation process.
  • causes of the expressed symptomatology from the production of soluble fibrin include gram-negative bacteria, mycoplasma and Candida albicans, which may flourish in the immune-compromised environment created by excess wastes and fibrin, and is related to the cellular destruction and by-products of ongoing free radical activity.
  • fibrinolytic agents will increase immune regulation and the effectiveness of white cell activity, improve capillary circulation and nutrient flow to the body's organs, aid in eliminating toxins, and enhance the benefits of other therapeutic agents.
  • fibrinolytic agents will reduce the amount of free radical soluble fibrin that accelerates degenerative oxidation, and can increase the body's immune effectiveness in combating cancer growth.
  • the invention provides a method for treating or preventing a disorder in an animal (e.g., human, dog, cat, horse, cow, chicken, etc.) by administering to the animal a therapeutically effective amount of phyto-percolate or derivative thereof.
  • the phyto-percolate of this invention is a complex aqueous mixture of micro- and macronutrient, including macromolecules (e.g., proteins, glycoproteins, lipids, polysaccharides, etc.). It is these micro- and macronutrients that are the phyto-percolate derivatives.
  • One of the most prevalent classes of phyto-percolate derivatives is protein.
  • the phyto-percolate is a protein or mixture " of proteins " that " naive an " apparent molecular weight of about 21.0 kDa and 67.5 kDa. Also included are homomultimers and heteromultimers such as homo- and hetero-dimers, homo- and hetero-trimers, homo- and hetero-tetramers, etc.
  • the phyto- percolate derivative has fibrinolytic activity or causes increased fibrinolytic activity in the animal or the cells exposed to the phyto-percolate or derivative thereof.
  • the phyto- percolate derivative may be isolated from the phyto-percolate or it may be produced by any appropriate method known in the art.
  • Suitable methods for producing the phyto-percolate derivative include, for example, recombinantly or naturally expressing the derivative (e.g., protein) using a microorganism, synthetically producing a derivative (i.e., chemical (cell- free) synthesis), extracting the derivative(s) from the culture media or cellular contents of one or more of the species present in ATCC Deposit #PTA-5863, or administering derivative together with live or processed cells or cell components.
  • the phyto-percolate derivati v e L pro !ucc ⁇ l uing o viicrt Organism may be used.
  • the phyto-percolate derivative is produced using a naturally-occurring species present in ATCC Deposit #PTA-5863, or a recombinant variant thereof.
  • a useful dosage of the phyto-percolate is between about 1 and about 20 ounces per day for a human or animal, preferably about 1 to about 4 ounces per day for a human.
  • the administered phyto-percolate contains between about 1 ppm and about 150 ppm of at least one phyto-percolate derivative.
  • a therapeutically effective amount of more than one phyto- percolate derivatives is administered.
  • the human or animal is administered between about ⁇ 1 mg and 1000 mg of the derivative per day.
  • Suitable methods for administration of the phyto-percolate or phyto-percolate derivative include, for example, oral (e.g., ingestion), sublingual, topical, rectal, bronchial (e.g., as an inhalant, nasal spray, etc), or vaginal administration as well as intravenous, intramuscular, and subcutaneous injection.
  • the phyto-percolate and phyto-percolate derivatives are particularly useful for the treatment of mastitis in cows.
  • the phyto-percolate or phyto-percolate derivative is administered directly to the lumen of the udder.
  • Another aspect of this invention is directed to a method of treating an overweight condition or obesity comprising administering to the animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • ' ⁇ ri' ⁇ 'tl ⁇ ' ⁇ f'aspect of ' this" invention is directed to a method for treating type I and II diabetes comprising administering to the animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating an inflammatory disorder comprising administering to the animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof. It is believed that the phyto-percolate and derivatives have broad spectrum anti-inflammatory properties and therefore may be used to reduce or prevent inflammation in a wide range of diseases, disorders and injuries.
  • Another aspect of this invention is directed to a method for treating a stomach disorder comprising administering to the animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Stomach disorders amenable to treatment with the phyto-percolate and/or derivatives thereof include, for example, a stomach ulcer and gastric reflux disease. . . .- . ⁇ ,. , .,
  • the phyto-percolate or derivatives may be used to alleviate side-effects or increase effectiveness of another primary therapy.
  • the phyto-percolate may be administered to reduce the oxidative stress, chemotherapy-induced nausea, chemotherapy-induced liver damage, appetite suppression, hair loss, fingernail and toenail loss and discoloration that result from anti-AIDS therapy and anti-cancer therapy (e.g., antiretroviral therapy, chemotherapy and radiation therapy).
  • the phyto-percolate or derivatives may be used to reduce the recovery time and soreness in animals (e.g., humans and horses) after periods of stress (e.g., exercise, performance, travel).
  • the phyto-percolate or derivatives are administered in order to restore physical energy, musculoskeletal function, immune function and mental acuity following periods of physical and mental stress.
  • the phyto-percolate or derivatives may be used to reduce the recovery time in animals (e.g., humans and horses) after periods of trauma (e.g., injury).
  • the phyto-percolate or derivatives are administered in order to aid in recovery, tissue repair, pain management, and excessive inflammation following tissue damage.
  • the phyto-percolate or derivates may also be administered topically directly to the eye (e.g., in the form of eye drops) to treat lesions or inflammation of the cornea, dry eyes, and similar ocular disorders.
  • Another aspect of this invention is directed to a method for treating conditions or disorders associated with infectious disease (e.g., viral, bacterial, or fungal infection) ⁇ ' ni'p ⁇ ; isMg'''adm ⁇ n ⁇ ste ⁇ ng"t ⁇ ""ffie animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • infectious disease e.g., viral, bacterial, or fungal infection
  • ⁇ ni'p ⁇ isMg'''adm ⁇ n ⁇ ste ⁇ ng"t ⁇ ""ffie animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Infectious disease may be the cause of many of the above and below listed diseases such as pneumonia, all viruses, acariosis, acne, adenovirus, AIDS, amebiasis, anthrax, athlete's food, babesiosis, bartonellosis, Bell's palsy, botulism, candidiasis, carbuncles, Chaga's disease, chicken pox, Chlamydia, coccidiomycosis, coronavirus, cryptococcosis, cytomegalovirus, Dengue fever, echovirus, erysipelas, furuncle, gangrene, Guillan-Barre syndrome, hepatitis, impetigo, influenza, leucopenia, Lyme's disease, malaria, martolditis, measles, mumps, mycobacterium, mycosis, parasites, pediculosis, P.I.D. pyodermia, rabies, rubella,
  • Another aspect of this invention is directed to a method for treating diseases related to the heart, blood vessels, renal, liver, and endocrine system comprising administering a therapeutically effective amount of :. « p''yk ⁇ -jien.' ⁇ l,i ⁇ e or deriv ⁇ I ' ve thereof .
  • Another aspect of this invention is directed to a method for treating a vasospasm comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating heart failure comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating cardiac hypertrophy comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating dysregulated blood pressure comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating angina comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating peripheral vascular disease comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating cerebral diseases and diseases related to the central nervous system that are vascular in origin comprising ⁇ administering to an animal (e.g., human) a therapeutically effective amount of a phyto- percolate or derivative thereof.
  • an animal e.g., human
  • Another aspect of this invention is directed to a method for treating neuro- degeneration comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating Alzheimer's disease comprising administering to an animal (e.g., human) a therapeutically effective amount of a compound of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating depression and/or anxiety comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • an animal e.g., human
  • Another aspect of this invention is directed to a method for treating addiction and drug-related afflictions incli ⁇ ' ⁇ : IL" ??MJ ⁇ pld. the 'ihuse -Of ⁇ nic ⁇ ine, cocaine, methamphetamines, opiates and alcohol comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • the phyto-percolate or derivatives are administered in order to aid in drug detoxification comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating attention deficit disorder and attention deficit hyperactivity disorder comprising administering to an animal (e.g., human) a therapeutically effective amount of a compound of a phyto-percolate or derivative thereof.
  • an animal e.g., human
  • Another aspect of this invention is directed to a method for treating sleep disorders comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating seasonal affective disorder comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating environmental and food allergies comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating conditions related to pain or nocioception comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Ari" ⁇ tn ' er " aspect " bf " fhis invention is directed to a method for treating migraine and tension headaches comprising administering to an animal (e.g., human) a therapeutically effective amount of a compound of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating disorders related to disruption of circadian rhythms including jet lag comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • an animal e.g., human
  • Another aspect of this invention is directed to a method for treating bodily oxidative stress and its symptoms associated with travel (e.g. fatigue, lack of physical energy) comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • the phyto-percolate or derivatives are administered in order to prevent infectious diseases associated with travel comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative th..:v> " .
  • Another aspect of this invention is directed to a method for treating diseases related to abnormal gastrointestinal motility, secretion, and/or function comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • an animal e.g., human
  • Another aspect of this invention is directed to a method for treating diarrhea and/or incontinence comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating a gastric ulcer comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • an animal e.g., human
  • Another aspect of this invention is directed to a method for treating irritable bowel syndrome comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating inflammatory bowel disease comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating nausea or vertigo comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • ⁇ rioth ' er "" " asp ect "" of " t ⁇ s invention is directed to a method for treating sexual dysfunction comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for altering fertility comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate or derivative thereof.
  • Another aspect of this invention is directed to a method for treating conditions or disorders associated with the immune system comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate.
  • Immune system deficiency may be the cause of many of the above and below listed diseases such as cancer, emphysema, encephalitis, environmental sensitivity, erysipelas, food poisoning and Reynaud's disease.
  • a 1 ' ; l ⁇ v.. ⁇ ' ⁇ .* i. r : ' Yv;-; :i o to a method for treating conditions or disorders associated with hormonal imbalances comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate.
  • Hormonal imbalances may be the cause of many of the above and below listed diseases such as acne, Addison's disease, endometriosis, Grave's disease, osteoporosis, menstrual and menopausal regulation, glucose, and other metabolic regulation.
  • the phyto-percolate and derivatives may be used to improve the general health and overall function of metabolic organs like the kidney, liver, and pancreas. It is believed that the phyto-percolate and derivatives improve the efficiency of those organs and increases their metabolic and endocrine functions.
  • Another aspect of this invention is directed to a method for treating conditions or disorders associated with neurological deficiencies comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate.
  • Neurological deficiencies may be the cause of many of the above and below listed diseases such as Lou Gehrig's disease, chronic pain, Huntingdon's Chorea, diabetic neuropathy, multiple sclerosis, Myasthenia Gravis, Parkinson's disease, poliomyelitis, senile dementia, nigrostriatal degeneration, stroke, tardive dyskinesia and tinnitus.
  • Another aspect of this invention is directed to a method for treating respiratory diseases comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate.
  • Another aspect of this invention is directed to a method for treating asthma comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate.
  • Another aspect ot this invention is directed to a method for treating diseases related to abnormal hormone release and utilization or endocrine function comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate.
  • Another aspect of this invention provides a method for treating abnormal insulin release or utilization, including insulin resistance, comprising administering to an animal (e.g., human) a therapeutically effective amount of a compound of a phyto-percolate.
  • an animal e.g., human
  • a therapeutically effective amount of a compound of a phyto-percolate comprising administering to an animal (e.g., human) a therapeutically effective amount of a compound of a phyto-percolate.
  • Another aspect of this invention is directed to a method for treating skin lesions, infections, inflammation and other skin disorders comprising administering to an animal (e.g., human) a therapeutically effective amount of a phyto-percolate.
  • Another aspect of this invention is directed to a method for supporting fetal development during pregnancy comprising administering to an animal (e.g., human) a therapeutically effective amount of a compound of a phyto-percolate.
  • Another aspect of lI,L Li ⁇ ⁇ >? ' " -' ! ⁇ ,'i i. ⁇ d to n ⁇ ie'n ⁇ tf r w v ⁇ . -sing the deleterious effects of a systemic or local microbial (e.g., bacterial, viral, or fungal) infection comprising administering to an animal (e.g., human) a therapeutically effective amount of a compound of a phyto-percolate.
  • Such treatment improves or normalizes organ structure and/or function.
  • Another aspect of this invention is directed to a method for supporting musculoskeletal rehabilitation following trauma or degenerative disease processes comprising administering to an animal (e.g., human) a therapeutically effective amount of a compound of a phyto-percolate.
  • an animal e.g., human
  • Another aspect of this invention is directed to a method for aiding in normalizing hyper-coagulant states including those secondary to endothelial destruction, lipid imbalance and dysfunction, oxidation, and mineral imbalance, comprising administering to an animal (e.g., human) a therapeutically effective amount of a compound of a phyto-percolate.
  • an animal e.g., human
  • a method of making the inventive phyto- percolate is disclosed.
  • the phyto-percolate is prepared by cultivating a mixture of freshwater algae and bacteria that is augmented by a nutrient blend that is related to the ''pi ⁇ Suct ⁇ ori''oFpl ! iy ⁇ o-pefcbTate ' ' ' de ⁇ vatives, forming a fortified algae culture.
  • Added to this fortified algal and bacterial culture is purified fresh water that has been purified by reverse osmosis, distillation, deionization or other means.
  • the culture is percolated with said purified fresh water and nutrient blend for a predetermined time forming a phyto-percolate that is biologically active in nature.
  • the phyto-percolate is decanted from the fortified algal and bacterial culture and processed. Suitable methods of processing the phyto-percolate include filtration, centrifugation, lyophilization, purification, evaporation, concentration, dilution, and other methods.
  • the filtering of the decanted phyto-percolate in one particular embodiment is by micro-filtration where the micro-filtration removes particles larger than about 0.22 ⁇ m.
  • this invention provides a substantially pure phyto-percolate derivative isolated from a phyto-percolate.
  • the derivative is isolated from the percol.u' ; rnd ⁇ oiy hy > tilbring- ihe niier ⁇ organisr.ih of ATCC Deposit #PTA-5863 or other appropriate species as described herein.
  • the derivative is a protein having a molecular weight of about 67.5 kDa.
  • two, three, four, five, or more phyto-percolate derivatives are produced and isolated from the culture at ATCC Deposit #PTA-5863.
  • the invention provides a composition comprising one or more phyto-percolate derivatives dissolved in an aqueous solution, wherein the solution comprises less than 150 ppm total dissolved solids.
  • the invention provides a pharmaceutical formulation comprising a one or more (e.g., two, three, four, five, or more) substantially pure derivatives isolated from a phyto-percolate and a pharmaceutically acceptable excipient.
  • inflammatory disorder encompasses a variety of conditions including conditions related to a hyperactive immune system, chronic inflammation, and autoimmune disorders.
  • Inflammatory disorders include, for example, acne vulgaris; acute febrile neutrophilic dermatosis; acute respiratory distress syndrome; Addison's disease; adrenocortical insufficiency; adrenogenital ayndrome; allergic conjunctivitis; allergic rhinitis; allergic intraocular inflammatory diseases, ANCA-associated small-vessel vasculitis; angioedema; ankylosing spondylitis; aphthous stomatitis; arthritis, asthma; atherosclerosis; atopic dermatitis; autoimmune disease; autoimmune hemolytic anemia; autoimmune hepatitis; Behcet's disease; Bell's palsy; berylliosis; balanitis circumscripta plasmacellularis; balanoposthitis; bronchial asthma; bullous herpetiformis dermatitis
  • obstructive pulmonary disease ocular inflammation; organ transplant rejection; osteoarthritis; pancreatitis; pemphigoid gestationis; pemphigus vulgaris; polyarteritis nodosa; polymyalgia rheumatica; primary adrenocortical insufficiency; primary billiary cirrhosis; pruritus scroti; pruritis/inflammation, psoriasis; psoriatic arthritis; Reiter's disease; relapsing polychondritis; pyoderma gangrenosum; rheumatic carditis; rheumatic fever; rheumatoid arthritis; rosacea caused by sarcoidosis; rosacea caused by scleroderma; rosacea caused by Sweet's syndrome; rosacea caused by systemic lupus erythematosus; rosacea caused by urtic
  • substantially pure when referring to a phyto-percolate derivative, means the state of a substance that has been separated from the other components of the phyto- percolate.
  • a substantially pure derivative is at least 80%, by weight, free from the proteins and other organic molecules of the phyto-percolate.
  • the substantially pure derivative is at least 90%, 95%, or 99%, by weight, free from those organic molecules.
  • a substantially pure derivative may be obtained, for example, by extracting it from a source other than the phyto-percolate.
  • the invention calls for more than one " su5sta ⁇ tially "" p ⁇ re " phy ⁇ -perc ⁇ Tat ' e " derivative, it is understood that the combination of derivatives is substantially pure relative to the phyto-percolate.
  • FIGURE 1 is an HPLC chromatogram of the phyto-percolate
  • FIGURE 2 is an FTIR spectrum of the phyto-percolate
  • FIGURE 3 is a [ 1 H]-NMR spectrum of the phyto-percolate.
  • a phyto-percolate is derived from a culture comprised of freshwater algae, moss, bacteria, actinomycetes, and fungi. It is believed that the culture is comprised of at least one or more of the following genera:
  • a heterotrophic rotifer species exists in the cultures, as well as bacteria that have been identified as Stenotrophomonas, Ralstonia, Acinetobacter, Acinetobacter, Leifsonia, Riemerella, Variovorax, and Streptomyces. Without being bound to any particular theory, it is believed that these bacteria may produce enzymes or other derivatives that are contributors to the effectiveness of the phyto-percolate.
  • Phyto-percolate cultures of approximately 100-200 ml of dense algal cells in approximately 2.5 gal (about 10 liters), of reverse-osmosis purified water are fed liquid extract of live active yeast, or Baker's yeast, Saccharomyces cerevisiae, which has been prepared from 1.0 g dry active yeast added to 50 ml warm water, at between about 37°C and about 43°C.
  • the mixture is allowed to incubate at room temperature for 10-30 minutes, or until it slightly foams.
  • the cultures are fed about 1 ml each, at a frequency of between every 1 to every 8 weeks It is contemplated within the scope of the invention that other yeast cultures may be used.
  • organic nutrients or substrates known in the art may be used such as glucose or proteose, or other algal growth media prepared from inorganic nutrients, supplements, and/or vitamins, if they support the culture's production of phyto-percolate derivatives.
  • the cultures are grown under full-spectrum grow lights at about
  • the cultures are grown in clear glass fishbowl containers having a volume of approximately 2.5 gal with semi-transparent plastic lids, with the exception of about five 3mm holes in the lid for gas exchange.
  • Other culture containers, ingredients, conditions and methods known in the art may be used that allow the cells to grow in a manner in which the phyto-percolate derivatives are expressed.
  • Such methods may include larger batch, semi-continuous, continuous or other type culture systems including bioreactors, photoreactors, or other fermentation technology, and may or may not include aeration or agitation, may or may not include solid, liquid, semi-solid or other form of growth media, substrate or carrier, may or may not include the above particular conditions of temperature, volume, contact time, nutrient supplementation, surface area, pH, light intensity or other environmental parameters.
  • the cultures are harvested periodically by drawing off the top 1.25 gal of phyto-percolate from each 2.5 gal culture. This is referred to as the "raw phyto-percolate.”
  • the majority of the algal or other cells forming the phyto-percolate culture remain in the bottom of the culture container substantially undisturbed while the phyto-percolate is c ⁇ ⁇ /uV '.
  • TV : , ⁇ ;h!ed- ma ⁇ e ⁇ -ai ' is 'lhen pn. ⁇ ssed as desired.
  • the volume of the container is then returned to original volume with purified water at approximately room temperature (about 25°C).
  • Other culture and harvest systems, timetables, volumes and methods may be used for production of the phyto-percolated and its derivatives.
  • the patterns of harvest and feeding affect derivative production.
  • the food blend such as a liquid extract of active Baker's yeast, increases the active derivative in the phyto-percolate culture compared with other foods or nutrient blends.
  • the interaction between competing or cooperative organisms within the culture also may release, alter, or stimulate the expression of derivatives in phyto-percolate.
  • Methods for evaluating in vivo effects of phyto-percolate include peripheral blood observations on wet and dry blood smears, diagnostic and/or analytical blood tests, and various clinical observations and measurements such as body weight. Reductions in excess pathological fibrin and platelet aggregation have been observed, which are secondary to inflammation and tissue destruction.
  • the decanted fluid is filtered through a progressive series of depth and membrane filters made of chemically-inert low- protein binding, food-safe materials. These have been shown to protect in vivo efficacy, and provide a final filtration level of about 0.22 microns, as well as being chemically inert to ozonated water.
  • filters manufactured by Millipore Corporation Catalog #'s D00501S01, CVHIOlTPE and CVDIOlTPE, constructed of polypropylene and PVDF, are suitable.
  • filters know in the art may be used that are inert to the phyto-percolate derivatives and processing and sanitizing materials including, for example, ozonated water
  • the processing system requires sanitization to protect the integrity of phyto-percolate and its derivatives.
  • ozonated and chlorinated water are used for this purpose.
  • processing system is comprised of a series of food-safe filter housings and other plumbing and suitable mixing, bottling, transport or storage containers.
  • Filtration by size exclusion removes approximately >99.9% of contaminants such as bacteria, yeast and mold spores, and algal cells. It is also believed to preserve derivative activity if filter materials are made of sanitary low-protein-binding, chemically-inert materials.
  • the resulting liquid, the phyto-percolate is substantially comprised of water and the active derivatives.
  • the phyto-percolate, after passing through the finishing filter is then sampled, tested and stored before and after bottling.
  • the phyto-percolate is processed and bottled under sanitary conditions known in the art using chemical sterilization. It is contemplated within the scope of the invention that other methods of filtration and sanitization known in the art may be used that are not unreasonably degrading of the derivative activity.
  • the phyto-percolate is bottled and distributed or otherwise processed, until consumption. Any suitable method of processing, packing, bottling, storing, distributing and transporting known in the art may be used.
  • Phyto-Percolate Characterization It is believed that the raw phyto-percolate, prior to filtration, is a complex mixture of macro- and micro-molecules. We performed several physico-chemical tests to determine the composition of the filtrate. In each case, the phyto-percolate filtrate was lyophilized, redissolved in ddH 2 O, and refiltered to remove any undissolved particulate matter. A sample of the lyoph ⁇ lized phyto-percolate was subjected to isocratic reverse phase HPLC, on a size-exclusion chromatography column (TSK-GEL Super SW Series; Tosoh Biosciences, Montgomeryville, PA), under non-denaturing conditions. Proteins were identified using a micro flow cell UV detector at 280 nm.
  • a major protein species of 67.5 IcDa was identified (retention time 18.747 minutes).
  • the 67.5 kDa peak contributed about 90% of the total signal measured at 280 nm. Also detected were peaks at retention times of 21.544 minutes (21.0 kDa) and 23.957 minutes. Analysis under denaturing and other conditions indicates that the 21.0 IdDa species is a protein molecule and the 23.957 minute peak is primarily polysaccharide.
  • phyto-percolate derivatives The major components of the phyto-percolate (the 67.5 kDa protein, 21.0 kDa protein, and the polysaccharide identified at 23.957 minutes) are referred to herein as phyto-percolate derivatives and may contribute to the biological and therapeutic efficacy of the phyto-percolate.
  • FIGURE 2 shows a spectrum that is characteristic of a dissolved protein sample.
  • a 21 day study using twelve mature (12 month old) Sprague-Dawley rats was performed. Each animal was orally administered 10 ml/kg of undiluted and unfiltered phyto-percolate (i.e., raw phyto-percolate) for 14 days, followed by non-dosing for 7 days. Each animal was weighted daily and observed for signs of toxicity. As shown in more detail in Table 1, the rats lost an average of 33 grams (6.3%) of body weight over the initial 14 day dosing period. They immediately began to regain lost body weight upon cessation of phyto-percolate administration. By the 21 day time point (7 days of non-dosing), the rats had lost an average of 25 grams (4.7%) of initial body weight (i.e., gained an average of 8 grams since phyto-percolate cessation).
  • undiluted and unfiltered phyto-percolate i.e., raw phyto-percolate
  • test animals were observed for adverse reactions immediately after each dose and at 4 and 24 hours subsequent. Daily observation for adverse reactions was continued during the 7 day non-dosing period. Specifically, clinical observations for adverse reactions were made for respiration, motor activity, convulsions, reflexes, ocular signs, salivation, piloerection, analgesia, muscle tone, gastrointestinal effects, and skin/dermal alterations. Gastrointestinal effects were the only observed adverse reaction. Soft to loose stool was observed in all test animals. No other adverse reaction was observed.
  • a single-center, prospective, randomized, triple-masked, placebo-controlled parallel-group-design pilot clinical trial of the phyto-percolate was performed using two different batches of the phyto-percolate. This trial was conducted in accordance with FDA regulations and under a protocol approved by an Institutional Review Board (IRB).
  • IRS Institutional Review Board
  • Subjects Primary inclusion criteria were men and women having a body mass index (BMI) of 25-40 m/kg 2 , 18-70 years old (inclusive), and desirous of losing weight.
  • Major exclusion criteria were moderate to severe co-morbid disease (e.g., cancer); history of stroke, transient ischemic attack (TlA), or similar conditions; uncontrolled hypertension, insulin-dependent diabetes, renal disease, moderately severe cardiac disease, lupus, alcohol abuse, and current or recent use of certain medications including medications and/or supplements for weight loss, glucose management, or arthritis. Women were excluded if they were pregnant, nursing, or actively trying to become pregnant.
  • Protocol Patients were assigned to self-administer one ounce of filtered phyto- percolate or placebo three times each day (t.i.d.) on an empty stomach at least 30 minutes before a meal. Subjects were asked to participate in a reduced carbohydrate diet and light exercise program and complete a one-day-per-week Food Log and a daily Exercise Log for the duration of the clinical trial. Patients were evaluated during a baseline examination and then again at 2-week, 4-week, and 6-week visits. Evaluations included measurement of body weight, arm and waist circumference, and body fat measurements.
  • Test Materials The patients in the treatment groups were assigned one of two different lots (Batch 1 and Batch 2) of phyto-percolate prepared as described above. The placebo product was similar in appearance (color, viscosity, and odor) to the phyto- percolate. All test materials were dispensed in unlabeled blue bottles with instructions to refrigerate after opening.
  • Test subjects demonstrated an average of 2.6x (156%) and 1.7x (69%) improved glucose control at 4 weeks and 6 weeks, respectively, when compared to the placebo group. Furthermore, 6 of the 22 test subjects met the clinically important criterion of > 50% control over baseline.
  • Cyclooxygenase-2 (COX-2) is a key regulator of the inflammatory cascade. COX-2 inhibitors are believed to red'tco-mflai? 1 » ti i'r > i f - , ⁇ r* vstdp.t ⁇ nd ⁇ i ⁇ x eduction. In view of the adverse effects associated with mixed COX inhibitors (aspirin, ibuprofen, and naproxen) and the presently available COX-2-specific inhibitors (valdecoxib, celecoxib, rofecoxib), there is a need for improved anti-inflammatory therapies with fewer side effects. Five concentrations of the phyto-percolate were screened, using an in vitro assay, for COX-2 inhibition. Riendeau et al, Can. J. Physiol Pharmacol. 75: 1088-1095, 1997;
  • the incubation buffer contained 100 mM Tris-HCl
  • PGE 2 was quantified using an enzyme-linked immunoassay (EIA).
  • Sample 1 was a lyophilized sample of phyto-percolate that was reconstituted just prior to assay in a final assay volume of 100 ⁇ l.
  • Rofecoxib was used as a positive control for COX-2 inhibition.
  • the sample was assayed in five concentrations in duplicate and compared to reference standard.
  • the IC 5 0 value for Sample 1 was calculated using the assumption that the 67.5IdDa protein species is the active compound, resulting in an IC50 value of 1.54 ⁇ M
  • Lipoxygenases (15-LO & 5-LO) are key regulators of the inflammatory cascade. LIPOX inhibitors are believed to reduce inflammation by blocking leukotriene production. LIPOX inhibitors may be used instead of, or in conjunction with COX inhibitors to provide anti-inflammatory therapy.
  • the 15-LO assay measures the conversion of 256 ⁇ M linoleic acid to 13-HPODE.
  • the assay is incubated in phosphate-buffered saline buffer, pH 7.4 at 4°C. 13-HPODE was spectrophotometrically quantified and compared to reference compound PD-146176.
  • the 5-LO assay measures the conversion of arachidonic acid to LTB4, expressed by human PBML cells.
  • the reaction was incubated in Hank's Balanced Salt
  • Carageenan-Induced Paw Edema The carrageenan-induced paw edema assay was used as an in vivo indicator of the anti-inflammatory effects of the phyto-percolate.
  • Carrageenan induces local inflammation and edema when injected into..tb.e,.pa ⁇ ' vrf 0 ⁇ ⁇ rat. (D; Ros.%et al.,. 1071), ⁇ he development of paw edema is believed to be biphasic (Vinegar et al., 1969).
  • the initial phase is attributable to the local release of histamine and serotonin (Crunkhon et al., 1971) and the second phase is caused by prostaglandin release as a result of COX activation.
  • the second phase is measured as an increase in paw volume and has been demonstrated to be responsive to steroidal and non-steroidal anti-inflammatory agents.
  • Groups of test subjects received oral doses of either vehicle control (water; 5 ml/kg), indomethacin (30 mg/kg), aspirin (100 mg/kg), unfiltered phyto-percolate (10 ml/kg), or filtered phyto-percolate (10 ml/kg) 30 minutes prior to intraplantar administration of carrageenan (0.1 ml of a 1% solution). Paw volume was measured at 0, 2, 4, 6, 8, and 20 hours after treatment using a plesthysmometer to measure volume displacement. Each treatment group is compared to control.
  • the effect of treatment using the phyto-percolate was investigated using a rat model of HIV infection.
  • the HIV model used inoculates rats with seven (7) of the nine (9) HIV genes, making it a non-contagious model that develops full symptoms of HIV by 9 months after inoculation, with a life expectancy of 12 months.
  • liver function tests including AST, ALT, GGTP, bilirubin, and albumin were monitored in the treatment and control groups.
  • C-reactive protein was assayed as an inflammatory marker.
  • the immune response was monitored using IgG, IgA, and IgM levels which are known to decline during the progression of AIDS.
  • serum was drawn by cardiac puncture for baseline (pre-inoculation) values.
  • the treatment group received phyto-percolate for their drinking water, which was allowed ad libitum, while the control group received filtered water.
  • Serum was drawn by cardiac puncture, as above, every thirty (30) days until the termination of the study.
  • the treatment group had an average 30% increase in IgA levels, 50% increase in IgG levels, and a 40% reduction in C- reactive protein (C-RP) levels, relative to the untreated group (Table 13). No significant differences in body weight, average daily food consumption, or average daily liquid consumption were detected between the groups.
  • the phyto-percolate dosaee will varv with f he nature and severity of the disease, the biochemical activity of the disease, and the age and weight of the subject.
  • the effects of using the phyto-percolate will be measured using standard parameters known in the art for any such disease state.
  • one derivative, the 67.5 kDa species is normally present in the phyto-percolate at about 10 ppm to about 150 ppm as measured by HPLC and UV detection (described above).
  • the concentration of phyto-percolate may be altered. For example, a large sample of the phyto-percolate may be partially dried in order to concentrate the therapeutically active derivatives so that they may be administered in a more convenient liquid dosage size.
  • the solid fraction is isolated from the phyto-percolate (e.g., by complete drying) and formulated for oral or parenteral administration (e.g., intravenous, intramuscular, and subcutaneous injection, topical, rectal or vaginal administration or other).
  • parenteral administration e.g., intravenous, intramuscular, and subcutaneous injection, topical, rectal or vaginal administration or other.
  • Methods well known in the art for making formulations are found, for example, in Remington: The Science and Practice of Pharmacy (21st edition), ed. R. Hendrickson, 2005, Lippincott Williams & Wilkins, Baltimore, MD.
  • Compositions intended for oral use may be prepared in solid or liquid forms according to any method known to the art for the manufacture of pharmaceutical compositions.
  • compositions may optionally contain sweetening, flavoring, coloring, perfuming, and/or preserving agents in order to provide a more palatable preparation.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is admixed with at least one inert pharmaceutically acceptable carrier or excipient.
  • inert pharmaceutically acceptable carrier or excipient may include, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, sucrose, starch, calcium phosphate, sodium phosphate, or kaolin. Binding agents, buffering agents, and/or lubricating agents (e.g., magnesium stearate) may also be used.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and soft gelatin capsules. These forms contain inert diluents commonly used in the art, such as water or an oil medium. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying agents, and suspending agents. Formulations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
  • suitable vehicles include propylene glycol, polyethylene glycol, vegetable oils, gelatin, hydrogenated naphalenes, and injectable organic esters, such as elbyl el ;/ 1 "vh " ornniaHops :n&y ⁇ . also contain adjuvants, such as preserving, wetting, emulsifying, and dispersing agents.
  • Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds.
  • an oral dosage of the phyto-percolate or derivative is typically administered on an empty stomach. Dosing on an empty stomach is most desirable because of the potential for interference on phyto-percolate absorption or function.
  • the active phyto-percolate derivatives may be inhibited by food-stimulated gastrointestinal activities, by adsorption of phyto-percolate derivatives to food particles, or by pharmacological inhibition by food components (e.g., ions or inhibitory macromolecules).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention se rapporte de manière générale à un procédé de préparation d'un phyto-percolate qui est dérivé d'un mélange à base d'eau fraîche contenant des algues. Cette invention se rapporte également à l'utilisation de ce phyto-percolate pour traiter divers états pathologiques. Ce phyto-percolate est supposé présenter une activité qui induit la réduction de la fibrine soluble et de la fibrine insoluble. En outre, on suppose que ce phyto-percolate réduit le stress oxydatif dans le corps.
PCT/US2006/015302 2004-04-23 2006-04-20 Composition et utilisation de phyto-percolate pour le traitement d'une maladie WO2006113925A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002625818A CA2625818A1 (fr) 2005-04-20 2006-04-20 Composition et utilisation de phyto-percolate pour le traitement d'une maladie
EP06758513A EP1928247A4 (fr) 2005-04-20 2006-04-20 Composition et utilisation de phyto-percolate pour le traitement d'une maladie
US12/067,735 US8586053B2 (en) 2005-09-21 2006-04-20 Composition and use of phyto-percolate for treatment of disease
US11/606,676 US7807622B2 (en) 2004-04-23 2006-11-30 Composition and use of phyto-percolate for treatment of disease
US12/897,574 US8791060B2 (en) 2004-04-23 2010-10-04 Composition and use of phyto-percolate for treatment of disease
US14/558,516 US10166270B2 (en) 2004-04-23 2014-12-02 Composition and method for affecting cytokines and NF-κB

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
USPCT/US2005/13375 2005-04-20
PCT/US2005/013375 WO2005112987A2 (fr) 2004-04-23 2005-04-20 Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie
US71902505P 2005-09-21 2005-09-21
US60/719,025 2005-09-21
US74177405P 2005-12-02 2005-12-02
US60/741,774 2005-12-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/013375 Continuation-In-Part WO2005112987A2 (fr) 2004-04-23 2005-04-20 Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2005/013375 Continuation-In-Part WO2005112987A2 (fr) 2004-04-23 2005-04-20 Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie
US11/606,676 Continuation-In-Part US7807622B2 (en) 2004-04-23 2006-11-30 Composition and use of phyto-percolate for treatment of disease
AU2006320264A Division AU2006320264A1 (en) 2005-04-20 2006-12-04 Composition and use of phyto-percolate for treatment of disease

Publications (2)

Publication Number Publication Date
WO2006113925A2 true WO2006113925A2 (fr) 2006-10-26
WO2006113925A3 WO2006113925A3 (fr) 2007-06-14

Family

ID=37115978

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/015302 WO2006113925A2 (fr) 2004-04-23 2006-04-20 Composition et utilisation de phyto-percolate pour le traitement d'une maladie

Country Status (2)

Country Link
EP (1) EP1928247A4 (fr)
WO (1) WO2006113925A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008040516A3 (fr) * 2006-10-02 2008-05-22 Fritzmeier Georg Gmbh & Co Kg Composition microbiologique et son utilisation
US7807622B2 (en) 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US8586053B2 (en) 2005-09-21 2013-11-19 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
US10842179B2 (en) 2010-02-22 2020-11-24 Zivo Bioscience, Inc. Agents and mechanisms for treating hypercholesterolemia
US11065287B2 (en) 2015-02-16 2021-07-20 Zivo Bioscience, Inc. Methods of modulating immune and inflammatory responses via administration of an algal biomass
US11806375B2 (en) 2016-02-16 2023-11-07 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645506B1 (en) * 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
EP1212093B1 (fr) * 1999-08-26 2004-07-07 Ganeden Biotech, Inc. Utilisation d'huile d'emeu et de ses diverses fractions comme excipient pour des medicaments et des preparations antifongiques, antibacteriennes et antivirales
CA2564466A1 (fr) * 2004-04-23 2005-12-01 Health Enhancement Products, Inc. Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP1928247A4
WONKEUK KIM ET AL.: "Purification and Characterization of a Fibrinolytic Enzyme produced from Bacillus sp. Strain CK 11-4 Screened from chungkook-Jang", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 62, no. 7, 1 July 1996 (1996-07-01), pages 2482 - 2488

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807622B2 (en) 2004-04-23 2010-10-05 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US8791060B2 (en) 2004-04-23 2014-07-29 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
US10166270B2 (en) 2004-04-23 2019-01-01 Zivo Bioscience, Inc. Composition and method for affecting cytokines and NF-κB
US8586053B2 (en) 2005-09-21 2013-11-19 Health Enhancement Products, Inc. Composition and use of phyto-percolate for treatment of disease
WO2008040516A3 (fr) * 2006-10-02 2008-05-22 Fritzmeier Georg Gmbh & Co Kg Composition microbiologique et son utilisation
US10842179B2 (en) 2010-02-22 2020-11-24 Zivo Bioscience, Inc. Agents and mechanisms for treating hypercholesterolemia
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
US10765732B2 (en) 2013-06-13 2020-09-08 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
US11065287B2 (en) 2015-02-16 2021-07-20 Zivo Bioscience, Inc. Methods of modulating immune and inflammatory responses via administration of an algal biomass
US11806375B2 (en) 2016-02-16 2023-11-07 Zivo Bioscience, Inc. Nutritional support for animals via administration of an algal derived supplement

Also Published As

Publication number Publication date
EP1928247A4 (fr) 2009-10-28
WO2006113925A3 (fr) 2007-06-14
EP1928247A2 (fr) 2008-06-11

Similar Documents

Publication Publication Date Title
US8791060B2 (en) Composition and use of phyto-percolate for treatment of disease
CA2631773C (fr) Composition et utilisation d'un phyto-percolate pour le traitement d'une maladie
US8586053B2 (en) Composition and use of phyto-percolate for treatment of disease
WO2006113925A2 (fr) Composition et utilisation de phyto-percolate pour le traitement d'une maladie
CN102671009B (zh) 植物发酵提取物及其粉末以及其组合物的制造方法
CN102215853A (zh) 来自佛手柑果的植物复合物、制造方法及作为膳食补充剂和在制药领域中的应用
CN106413724A (zh) 与多糖聚合物粘合剂缀合的鼠李糖乳杆菌rht‑3201，及其用于预防或治疗特应性疾病的用途
US10166270B2 (en) Composition and method for affecting cytokines and NF-κB
CN112546052A (zh) 一种含有海洋寡糖防治痛风的组合物
US20080031863A1 (en) Method of Preparation and Use of Fibrinolytic Enzymes in the Treatment of Disease
WO2016053142A1 (fr) Composition de purification de l'organisme
WO2015190872A1 (fr) Composition pharmaceutique contenant un extrait de spirulina maxima en tant que principe actif pour le traitement et la prévention de l'obésité
JP2006526392A (ja) 生物活性油
CA2776919C (fr) Composition nutraceutique a base d'extrait de shilajit, d'acide folique, de vitamine b12 et de vitamine b6 et son utilisation pour prevenir et/ou traiter des maladies neurodegener atives et/ou la deterioration cognitive associee au vieillissement cerebral
Agboola et al. Purified Azadirachta indica leaf arginase exhibits properties with potential tumor therapeutics: An Invitro Study
CN114699424A (zh) 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用
AU2013204257A1 (en) Composition and use of phyto-percolate for treatment of disease
CN108785333B (zh) 一种提升认知和记忆能力的保健品组合物及制备方法
Al-Jowari Comparative investigation of amoxicillin and cephalexin administration on some biochemical parameters in male rabbits
RU2812570C1 (ru) Применение 3-амино-4-(5-метил-2-фурил)-5,6,7,8-тетрагидротиено[2,3-b]хинолин-2-ил](фенил)метанон в качестве противовоспалительного средства
Ojo et al. Evaluation of transaminases activity of aqueous extract of Ocimum gratissimum in the liver and kidney of Albino Rats
RU2432957C2 (ru) Способ получения средства, обладающего гастрозащитной активностью
Can et al. Molecular docking study on acetylcholinesterase and urease enzyme inhibition effects of Amygdalin
Sripriya et al. In Vitro Screening of 20 Indian Medicinal Plants for their Anti-Cholinesterase Effects
Ajibade et al. Some protective effects of lemon juice on ethylene glycol and amonium chloride induced kidney damage in adult Wistar rats

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11606676

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2006758513

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008532207

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2625818

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: JP

WWE Wipo information: entry into national phase

Ref document number: 12067735

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载